Anesthetic management of severe or worsening postpartum hemorrhage;Prise en charge anesthésique d'une hémorragie du post-partum sévère ou résistant au traitement médical

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 43, Issue 10, 2014, Pages 1030-1062

  Aya, A G ^a,d   Ducloy Bouthors, A S ^b   Rugeri, L ^c   Gris, J C ^a,d  

^a DEPARTMENT OF NEUROLOGY   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

Monitoring; Obstetric anesthesia; Postpartumhaemorrhage; Transfusion; Volume replacement

Indexed keywords

ANTIBIOTIC AGENT; FIBRINOGEN; FRESH FROZEN PLASMA; INFUSION FLUID;

ARTICLE; BLOOD CLOTTING DISORDER; BLOOD PRESSURE; BLOOD TRANSFUSION; DISEASE SEVERITY; DIURESIS; EPIDURAL CATHETER; GENITAL BLEEDING; HEART RATE; HUMAN; HYPOTHERMIA; OBSTETRIC ANESTHESIA; PALLOR; PATIENT MONITORING; POSTPARTUM HEMORRHAGE; ANESTHESIA; BLOOD COMPONENT THERAPY; DISEASE MANAGEMENT; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

ANESTHESIA; BLOOD COMPONENT TRANSFUSION; DISEASE MANAGEMENT; HUMANS; POSTPARTUM HEMORRHAGE; PRACTICE GUIDELINES AS TOPIC;

EID: 84920115546     PISSN: 03682315     EISSN: 17730430     Source Type: Journal    
DOI: 10.1016/j.jgyn.2014.10.004     Document Type: Article

References (172)

1. Rackelboom T, Marcellin L, Benchetrit D, Mignon A. Prise encharge initiale par l'anesthésiste-réanimateur d'une hémor-ragie du post-partum dans les suites d'un accouchementpar voie basse. J Gynecol Obstet Biol Reprod (Paris) 2014, http://dx.doi.org/10.1016/j.jgyn.2014.09.027.
2. Boulay G, Hamza J. Prise en charge anesthésique en casd'hémorragie du post-partum qui persiste ou qui s'aggravemalgré les mesures initiales. J Gynecol Obstet Biol Reprod2004; 33: 4S80-88S.
3. Pacagnella RC, Souza JP, Durocher J, Perel P, Blum J, Wini-koff B, et al. A systematic review of the relationship betweenblood loss and clinical signs. PLoS One 2013; 8: e57594.
4. Gayat E, Resche-Rigon M, Morel O, Rossignol M, Mantz J, Nicolas-Robin A, et al. Predictive factors of advanced inter-ventional procedures in a multicentre severe postpartumhaemorrhage study. Intens Care Med 2011; 37: 1816-25.
5. Peyton PJ, Chong SW. Minimally invasive measurement of car-diac output during surgery and critical care: a meta-analysisof accuracy and precision. Anesthesiology 2010; 113: 1220-35[Erratum in: Anesthesiology 2012; 116: 973].
6. Zhou X, Yan H, Xing Y, Dang S, Zhuoma B, Wang D. Evalua-tion of a portable hemoglobin photometer in pregnant womenin a high altitude area: a pilot study. BMC Public Health2009; 9: 228.
7. Rippmann CE, Nett PC, Popovic D, Seifert B, Pasch T, Spahn DR. HemoCue®, an accurate bedside method of hemoglobinmeasurement? J Clin Monit 1997; 13: 373-7.
8. Conway AM, Hinchliffe RF, Earland J, Anderson LM. Measu-rement of haemoglobin using single drops of skin punctureblood: is precision acceptable? J Clin Pathol 1998; 51: 248-50.
9. Coquin J, Bertarerex A, Dewitte A, Lefèvre L, Joannes-BoyauO, Fleureau C, et al. Accuracy of determining hemoglobinlevel using occlusion spectroscopy in patients with severegastrointestinal bleeding. Anesthesiology 2013; 118: 640-8.
10. McNulty SE, Torjman M, Grodecki W, Marr A, Schieren H. Acomparison of four bedside methods of hemoglobin assess-ment during cardiac surgery. Anesth Analg 1995; 81: 1197-202.
11. Jeager M, Ashbury T, Adams M, Duncan P. Perioperative on-sitehaemoglobin determination: as accurate as laboratory values?Can J Anaesth 1996; 43: 795-8.
12. Lardi AM, Hirst C, Mortimer AJ, McCollum CN. Evaluationof the HemoCue®for measuring intra-operative haemoglo-bin concentrations: a comparison with the coulter Max-M®. Anaesthesia 1998; 53: 349-52.
13. Teli M, Ng Y, Ingram R. Evaluation of the HemoCue®portablehemoglobinometer after major joint arthroplasty. J Arthro-plasty 2002; 17: 224-6.
14. Srinivasan NM, Kasturba MP. Intra-operative point of carehaemoglobin estimation: a comparison of three Methods SriLankan J Anaesthesiol 2010; 18: 15-9.
15. Miller RD, Ward TA, Shiboski SC, Cohen NH. A comparison ofthree methods of hemoglobin monitoring in patients under-going spine surgery. Anesth Analg 2011; 112: 858-63.
16. Lamhaut L, Apriotesei R, Combes X, Lejay M, Carli P, Vivien B. Comparison of the accuracy of noninvasive hemoglobinmonitoring by spectrophotometry (SpHb) and HemoCue®withautomated laboratory hemoglobin measurement. Anesthesio-logy 2011; 115: 548-54.
17. Coquin J, Dewitte A, Manach YL, Caujolle M, Joannes-Boyau O, Fleureau C, et al. Precision of non invasive hemoglobin-level measurement by pulse co-oximetry in patients admittedto intensive care units for severe gastrointestinal bleeds. CritCare Med 2012; 40: 2576-82.
18. Skelton VA, Wijayasinghe N, Sharafudeen S, Sange A, Parry NS, Junghans C. Evaluation of point-of-care haemoglobin measu-ring devices: a comparison of Radical-7TMpulse co-oxymetry, HemoCue®and laboratory haemoglobin measurements in obs-tetric patients. Anaesthesia 2013; 68: 40-5.
19. Giraud B, Frasca D, Debaene B, Mimoz O. Comparison of hae-moglobin measurement methods in the operating theatre. BrJ Anaesth 2013; 111: 946-54.
20. Causey MW, Miller S, Foster A, Beekley A, Zenger D, Martin M. Validation of noninvasive hemoglobin measurements using theMasimo Radical-7 SpHb Station. Am J Surg 2011; 201: 592-8.
21. Frasca D, Dahyot-Fizelier C, Catherine K, Levrat Q, DebaeneB, Mimoz O. Accuracy of a continuous noninvasive hemoglo-bin monitor in intensive care unit patients. Crit Care Med2011; 39: 2277-82.
22. Nguyen BV, Vincent JL, Nowak E, Coat M, Paleiron N, Gouny P, et al. The accuracy of noninvasive hemoglobin measurementby multiwavelength pulse oximetry after cardiac surgery. Anesth Analg 2011; 113: 1052-7.
23. Butwick A, Hilton G, Carvalho B. Non-invasive haemoglobinmeasurement in patients undergoing elective Caesarean sec-tion. Br J Anaesth 2012; 108: 271-7.
24. Vos JJ, Kalmar AF, Struys MM, Porte RJ, Wietasch JK, Scheeren TW, et al. Accuracy of non-invasive measurementof haemoglobin concentration by pulse co-oximetry duringsteady-state and dynamic conditions in liver surgery. Br JAnaesth 2012; 109: 522-8.
25. Moore LJ, Wade CE, Vincent L, Podbielski J, Camp E, Junco DD, et al. Evaluation of nininvasive hemoglobin measure-ments in trauma patients. Am J Surg 2013; 206: 1041-7.
26. Gayat E, Aulagnier J, Matthieu E, Boisson M, Fischler M. Non-invasive measurement of hemoglobin: assessmentof two different point-of-care technologies. PLoS One2012; 7: e30065.
27. Morey TE, Gravenstein N, Rice MJ. Let's think clinically ins-tead of mathematically about device accuracy. Anesth Analg2011; 113: 89-91.
28. Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors andreplacement of major blood loss with plasma-poor red cellconcentrates. Anesth Analg 1995; 81: 360-5.
29. de Lloyd L, Bovington R, Kaye A, Collis RE, Rayment R, Sanders J, et al. Standard haemostatic tests following major obstetrichaemorrhage. Int J Obst Anesth 2011; 20: 135-41.
30. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al. The decrease of fibrinogen is an early predictor ofthe severity of postpartum hemorrhage. J Thromb Haemost2007; 5: 266-73.
31. Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz RC, Bouvier-Colle MH, et al. Association between fibrinogen leveland severity of postpartum haemorrhage: secondary analysisof a prospective trial. Br J Anaesth 2012; 108: 984-9.
32. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilution-induced profibrinolytic state is mitigatedby fresh-frozen plasma: implications for early haemosta-tic intervention in massive haemorrhage. Br J Anaesth2010; 104: 318-25.
33. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CAA, De Robertis E, Filipescu DC, et al. Management of severeperioperative bleeding: guidelines from the European Societyof Anaesthesiology. Eur J Anaesth 2013; 30: 270-382.
34. Abdul-Kadir R, McLintock C, Ducloy AS, El-Refaey H, England A, Federici AB, et al. Evaluation and mana-gement of postpartum hemorrhage: consensus froman international expert panel. Transfusion 2014, http://dx.doi.org/10.1111/trf.12550.
35. Huissoud C, Carrabin N, Audibert F, Levrat A, Massignon D, Berland M, et al. Bedside assessment of fibrinogen levelin postpartum haemorrhage by thrombelastometry. BJOG2009; 116: 1097-102.
36. Huissoud C, Carrabin N, Benchaib M, Fontaine O, LevratA, Massignon D, et al. Coagulation assessment by rotationthrombelastometry in normal pregnancy. Thromb Haemost2009; 101: 755-61.
37. Armstrong S, Fernando R, Ashpole K, Simons R, ColumbM. Assessment of coagulation in the obstetric populationusing ROTEM®thromboelastometry. Int J Obstet Anesth2011; 20: 293-8.
38. Oudghiri M, Keita H, Kouamou E, Boutonnet M, Orsini M, Desconclois C, et al. Reference values for rota-tion thromboelastometry (ROTEM®) parameters followingnon-haemorrhagic deliveries. Correlation with standard hae-mostasis parameters. Thromb Haemost 2011; 106: 176-8.
39. de Lange NM, van Rheenen-Flach LE, Lancé MD, Mooyman L, Woiski M, van Pampus EC, et al. Peri-partum reference rangesfor ROTEM®thromboelastometry. BJA 2014; 112: 852-9.
40. Gorlinger K, Dirkmann D, Hanke AA, Kamler M, KottenbergE, Thielmann M, et al. First-line therapy with coagulationfactor concentrates combined with point-of-care coagulationtesting is associated with decreased allogeneic blood transfu-sion in cardiovascular surgery: a retrospective, single-centercohort study. Anesthesiology 2011; 115: 1179-91.
41. Afshari A, Wikkelsø A, Brok J, Møller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM®)to monitor haemotherapy versus usual care in patientswith massive transfusion. Cochrane Database Syst Rev2011; 3: CD007871.
42. Poller L, Keown M, Chauhan N, Van Den-Besselaar A, Tripodi A, Shiach C, et al. Reliability of international normalised ratiosfrom two-point of care test systems: comparison with conven-tional Methods Br Med J 2003; 327: 3035.
43. Plesch W, Wolf T, Breitenbeck N, Dikkenschei LD, Cervero A, Perez PL, et al. Results of the performance verification of theCoaguChek XS system. Thromb Res 2008; 123: 381-9.
44. Petersen JR, Vonmarensdorf HM, Weiss HL, Elghetany MT. Use of error grid analysis to evaluate acceptability of apoint of care prothrombin time meter. Clin Chim Acta2010; 411: 131-4.
45. Toulon P1, Ozier Y, Ankri A, Fléron MH, Leroux G, Samama CM. Point-of-care versus central laboratory coagulation testingduring haemorrhagic surgery. A multicenter study. ThrombHaemost 2009; 101: 394-401.
46. Weber CF, Zacharowski K. Perioperative point of care coagu-lation testing. Dtsch Arztebl Int 2012; 109: 369-75.
47. Reynolds L, Beckmann J, Kurz A. Perioperative complicationsof hypothermia. Best Pract Res Clin Anaesthesiol2008; 22: 645-57.
48. Rajagopalan S, Mascha E, Na J, Sessler DI. The effects ofmild perioperative hypothermia on blood loss and transfusionrequirement. Anesthesiology 2008; 108: 71-7.
49. Johnston TD, Chen Y, Reed 2nd RL. Functional equivalence ofhypothermia to specific clotting factor deficiencies. J Trauma1994; 37: 413-7.
50. Kirkpatrick AW, Chun R, Brown R, Simons RK. Hypothermiaand the trauma patient. Can J Surg 1999; 42: 333-43.
51. Sessler DI. Mild perioperative hypothermia. N Engl J Med1997; 336: 1730-7.
52. Halloran OJ. Warming our cesarean section patients: why andhow? J Clin Anesth 2009; 21: 239-41.
53. John M, Ford J, Harper M. Peri-operative warmingdevices: performance and clinical application. Anaesthesia2014; 69: 623-38.
54. Forbes SS, Eskicioglu C, Nathens AB, Fenech DS, Laflamme C, McLean RF, et al. Evidence-based guidelines for pre-vention of perioperative hypothermia. J Am Coll Surg2009; 209: 492-503.
55. James AH, Jamison MG, Brancazio LR, Myers ER. Venousthromboembolism during pregnancy and the postpartum per-iod: incidence, risk factors, and mortality. Am J ObstetGynecol 2006; 194: 1311-5.
56. Morris JM, Algert CS, Roberts CL. Incidence and risk factorsfor pulmonary embolism in the postpartum period. J ThrombHaemost 2010; 8: 998-1003.
57. Chauleur C, Cochery-Nouvellon E, Mercier E, Aya G, MarèsP, Mismetti P, et al. Analysis of the venous thromboembolismrisk associated with severe postpartum haemorrhage. ThrombHaemost 2008; 100: 773-9.
58. Sultan AA, Tata LJ, West J, Fiaschi L, Fleming KM, Nelson-Piercy C, et al. Risk factors for first venous thromboembolismaround pregnancy: a population-based cohort study from theUnited Kingdom. Blood 2013; 121: 3953-61.
59. Abbasi N, Balayla J, Laporta DP, Kezouh A, Abenhaim HA. Trends, risk factors and mortality among women withvenous thromboembolism during labour and delivery: apopulation-based study of 8 million births. Arch Gynecol Obs-tet 2014; 289: 275-84.
60. Deneux-Tharaux C, Bonnet MP, Tort J. Épidémiologie del'hémorragie du post-partum. J Gynecol Obstet Biol Reprod2014 [sous presse].
61. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatalrisk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6: 905-12.
62. ACOG Practice Bulletin. Clinical management guidelines forobstetrician-gynecologists number 76, October 2006: postpar-tum hemorrhage. Obstet Gynecol 2006; 108: 1039-47.
63. RCOG, Green Top Guideline No. 52. Prevention and manage-ment of postpartum haemorrhage; 2009 [Updated April 2011. Accessible à: http://www.rcog.org.uk].
64. RANZCOG College Statement: C-Obs 43 Management of post-partum haemorrhage (PPH); 2014. Accessible sur Internet à: http://www.ranzco.edu.au
65. SOGC clinical practice guideline No. 235. Active managementof the third stage of labour: prevention and treatment ofpostpartum hemorrhage. JOGC 2009; 31: 980-93 [Accessiblesur Internet à: http://www.sogc.org].
66. WHO guidelines for the management of postpartum haemor-rhage and retained placenta; 2012. Accessible sur Internet à: http://whqlibdoc.who.int/publications/2009/9789241598514eng.pdf
67. Mousa HA, Alfirevic Z. Major postpartum hemorrhage: surveyof maternity units in the United Kingdom. Acta Obstet GynecolScand 2002; 81: 727-30.
68. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, et al. VTE, thrombophilia, antithrombotictherapy, and pregnancy: Antithrombotic Therapy and Pre-vention of Thrombosis, 9th ed: American College of ChestPhysicians Evidence-Based Clinical Practice Guidelines. Chest2012; 141: e691S-736S.
69. Benhamou D, Mignon A, Aya G, Brichant JF, Bonnin M, Chau-leur C, et al. Maladie thromboembolique péri-opératoire etobstétricale. Pathologie gynécologique et obstétricale. AnnFr Anesth Reanim 2005; 24: 911-20.
70. Guyatt GH, Akl EA, Crowther M, Gutterman DD, SchünemannHJ, American College of Chest Physicians AntithromboticTherapy and Pevention of Thrombosis Panel. Antithrombo-tic therapy and prevention of thrombosis, 9th ed: AmericanCollege of Chest Physicians evidence-based clinical practiceguidelines. Chest 2012; 141: 7S-47S.
71. Saha P, Scott D, Atalla R. Haemostatic changes in the puer-perium '6 weeks postpartum' (HIP Study): inplication formaternal thromboembolism. BJOG 2009; 116: 1602-12.
72. Hahn RG. Volume kinetics for infusion fluids. Anesthesiology2010; 113: 470-81.
73. Woodcock TE, Woodcock TM. Revised Starling equation andthe glycocalyx model of transvascular fluid exchange: animproved paradigm for prescribing intravenous fluid therapy. Br J Anaesth 2012; 108: 384-94.
74. Lobo DN, Stanga Z, Aloysius MM, Wicks C, Nunes QM, Ingram KL, et al. Effect of volume loading with 1 liter intravenousinfusions of 0.9% saline, 4% succinylated gelatine (Gelofu-sine) and 6% hydroxyethyl starch (Voluven) on blood volumeand endocrine responses: a randomized, three-way crosso-ver study in healthy volunteers. Crit Care Med 2010; 38: 464-70.
75. Drobin D, Hahn RG. Volume kinetics of Ringer's solu-tion in hypovolemic volunteers. Anesthesiology 1999; 90: 81-91.
76. Svensen CHI, Rodhe PM, Olsson J, Børsheim E, Aarsland A, Hahn RG. Arteriovenous differences in plasma dilution andthe distribution kinetics of lactated ringer's solution. AnesthAnalg 2009; 108: 128-33.
77. Norberg A, Hahn RG, Li H, Olsson J, Prough DS, Børsheim E, et al. Population volume kinetics predicts retention of 0.9%saline infused in awake and isoflurane-anesthetized volun-teers. Anesthesiology 2007; 107: 24-32.
78. Drobin D, Hahn RG. Distribution and elimination of crystalloidfluid in pre-eclampsia. Clin Sci 2004; 106: 307-13.
79. Chappell D, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M. Arational approach to perioperative fluid management. Anes-thesiology 2008; 109: 723-40.
80. Myburgh J, et al. Hydroxyethyl starch or saline for fluid resus-citation in intensive care. N Engl J Med 2012; 367: 1901-11.
81. Perner A, Haase N, Guttormsten AB, Tenhunen J, Klemenzson G, Aneman A, et al. Hydroxyethyl starch 130/0, 42 versus Rin-ger's acetate in severe sepsis. N Engl J Med 2012; 367: 124-34.
82. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0.38-0.45 ver-sus crystalloid or albumin in patients with sepsis: systematicreview with meta-analysis and trial sequential analysis. BMJ2013; 346: f839.
83. Valley MA1, Bourke DL, Hamill MP, Raja SN. Time courseof sympathetic blockade during epidural anesthesia: laserDoppler flowmetry studies of regional skin perfusion. AnesthAnalg 1993; 76: 289-94.
84. Magnusdottir H, Kirnö K, Ricksten SE, Elam M. High tho-racic epidural anesthesia does not inhibit sympatheticnerve activity in the lower extremities. Anesthesiology1999; 91: 1299-304.
85. Nygard E1, Sejrsen P, Kofoed KF. Thoracic sympatholysiswith epidural blockade assessed by quantitative measure-ment of cutaneous blood flow. Acta Anaesthesiol Scand2002; 46: 1037-41.
86. Butterworth 4th JF, Piccione Jr W, Berrizbeitia LD, Dance G, Shemin RJ, Cohn LH. Augmentation of venous return byadrenergic agonists during spinal anesthesia. Anesth Analg1986; 65: 612-6.
87. Park GE, Hauch MA, Curlin F, Datta S, Bader AM. The effectsof varying volumes of crystalloid administration before cesa-rean delivery on maternal hemodynamics and colloid osmoticpressure. Anesth Analg 1996; 83: 299-303.
88. Faydaci F, Gunaydin B. Different preloading protocols withconstant ephedrine infusion in the prevention of hypotensionfor elective cesarean section under spinal anesthesia. ActaAnaesthesiol Belg 2011; 62: 5-10.
89. Kang YG, Abouleish E, Caritis S. Prophylactic intravenousephedrine infusion during spinal anesthesia for cesarean sec-tion. Anesth Analg 1982; 61: 839-42.
90. Mercier FJ, Riley ET, Frederickson WL, Roger-Christoph S, Benhamou D, Cohen SE. Phenylephrine added to prophylac-tic ephedrine infusion during spinal anesthesia for electivecesarean section. Anesthesiology 2001; 95: 668-74.
91. Ngan Kee WD, Lee A, Khaw KS, Ng FF, Karmakar MK, Gin T. Arandomized double-blinded comparison of phenylephrine andephedrine infusion combinations to maintain blood pressureduring spinal anesthesia for cesarean delivery: the effects onfetal acid-base status and hemodynamic control. Anesth Analg2008; 107: 1295-302.
92. Heesen M, Kölhr S, Rossaint R, Straube S. Prophylacticphenylephrine for caesarean section under spinal anaes-thesia: systematic review and meta-analysis. Anaesthesia2014; 69: 143-65.
93. Magder S. Phenylephrine and tangible bias. Anesth Analg2011; 113: 211-3.
94. Thiele RH, Nemergut EC, Lynch 3rd C. The physiologic impli-cations of isolated alpha(1) adrenergic stimulation. AnesthAnalg 2011; 113: 284-96.
95. Gelman S, Mushlin PS. Catecholamine-induced changes inthe splanchnic circulation affecting systemic hemodynamics. Anesthesiology 2004; 100: 434-9.
96. Thiele RH, Nemergut EC, Lynch 3rd C. The clinical impli-cations of isolated alpha(1) adrenergic stimulation. AnesthAnalg 2011; 113: 297-304.
97. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. Management of bleeding fol-lowing major trauma: an updated European guideline. CritCare 2010; 14: R52.
98. Bonnet MP, Deneux-Tharaux C, Bouvier-Colle MH. Criticalcare and transfusion management in maternal deaths frompostpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol2011; 158: 183-8.
99. Agence française de sécurité sanitaire des produits de santé(AFSSAPS). Transfusion de globules rouges homologues: pro-duits, indications, alternatives; 2002. http://ansmsantefr/var/ansmsite/storage/original/application/67bca30279b4b95b00cf19ae44c3a8cepdf
100. Agence nationale de sécurité du médicament et des produitsde santé (ANSM). Transfusion de plasma thérapeutique: pro-duits, indications. Actualisation; 2012.
101. Djoudi R. Gestion des produits sanguins en mater-nité. J Gynecol Obstet Biol Reprod (Paris) 2014, http://dx.doi.org/10.1016/j.jgyn.2014.10.006.
102. Kayem G, Keita H. Prise en charge des placenta prae-via et accreta. J Gynecol Obstet Biol Reprod (Paris) 2014, http://dx.doi.org/10.1016/j.jgyn.2014.10.007.
103. Bonnet MP, Deneux-Tharaux C, Dupont C, Rudigoz RC, Bouvier-Colle MH. Transfusion practices in postpartum hemor-rhage: a population-based study. Acta Obstet Gynecol Scand2013; 92: 404-13.
104. Williams J, Mozurkewich E, Chilimigras J, Van De Ven C. Critical care in obstetrics: pregnancy-specific condi-tions. Best Pract Res Clini Obstet Gynaecol 2008; 22: 825-46.
105. Goodnough LT, Daniels K, Wong AE, Viele M, Fon-Taine MF, Butwick AJ. How we treat: transfusion medi-cine support of obstetric services. Transfusion 2011; 51: 2540-8.
106. Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. The role of massive transfusion protocols in obstetrics. Am JPerinatol 2013; 30: 1-4.
107. Murad MH, Stubbs JR, Gandhi MJ, Wang AT, Paul A, ErwinPJ, et al. The effect of plasma transfusion on morbidity andmortality: a systematic review and meta-analysis. Transfusion2010; 50: 1370-83.
108. Davenport R, Curry N, Manson J, De'Ath H, Coates A, Rourke C, et al. Hemostatic effects of fresh frozen plasma may bemaximal at red cell ratios of 1: 2. J Trauma 2011; 70: 90-5[discussion 95-6].
109. Pasquier P, Gayat E, Rackelboom T, La Rosa J, Tashkandi A, Tesniere A, et al. An observational study of the fresh fro-zen plasma: red blood cell ratio in postpartum hemorrhage. Anesth Analg 2013; 116: 155-61.
110. Johansson PI, Oliveri RS, Ostrowski SR. Hemostatic resusci-tation with plasma and platelets in trauma. J Emerg TraumaShock 2012; 5: 120-5.
111. Faber MK, Sadana N, Kaufman RM, Liu X, Kodali BS. Transfu-sion ratios for postpartum hemodilutional coagulopathy: anin vitro thromboelastographic model. Am J Obstet Gynecol2014; 210, 323. e1-7.
112. Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, TøNnesen E, Ingerslev J, et al. Fibrinogen substitutionimproves whole blood clot firmness after dilution withhydroxyethyl starch in bleeding patients undergoing radicalcystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009; 7: 795-802.
113. Rourke C, Curry N, Khan S, Taylor R, Raza I, Davenport R, et al. Fibrinogen levels during trauma hemorrhage, responseto replacement therapy, and association with patient out-comes: fibrinogen levels during trauma hemorrhage. J ThrombHaemost 2012; 10: 1342-51.
114. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen andhemostasis: a primary hemostatic target for the managementof acquired bleeding. Anesth Analg 2012; 114: 261-74.
115. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutictarget for bleeding: a review of critical levels and replace-ment therapy: fibrinogen: a therapeutic target for bleeding. Transfusion 2014; 54: 1389-405.
116. Kelsey HA, Muirhead JM. Severe postpartum haemor-rhage associated with fibrinogen deficiency. Lancet1955; 269: 705-6.
117. Torrielli R, Boutin F, Rochet M, Neophytou P, Lahaye F. Acute fibrinopenia in obstetrics. Rev Fr Gynecol Obstet1988; 83: 509-13.
118. Bell SF, Rayment R, Collins PW, Collis RE. The use of fibrinogenconcentrate to correct hypofibrinogenaemia rapidly duringobstetric haemorrhage. Int J Obstet Anesth 2010; 19: 218-23.
119. Glover NJ, Collis RE, Collins P. Fibrinogen concentrateuse during major obstetric haemorrhage. Anaesthesia2010; 65: 1229-30.
120. Kikuchi M, Itakura A, Miki A, et al. Fibrinogen concentratesubstitution therapy for obstetric hemorrhage complicated bycoagulopathy. Obstet Gynaecol Res 2013; 39: 770-6.
121. Ahmed S, Harrity C, Johnson S, et al. The efficacy of fibri-nogen concentrate compared with cryoprecipitate in majorobstetric haemorrhage: an observational stydy. Transfus Med2012; 22: 344-9.
122. Peyvandi F. Epidemiology and treatment of congenital fibri-nogen deficiency. Thromb Res 2012; 130: S7-11.
123. Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondéjar E, et al. Management of bleeding andcoagulopathy following major trauma: an updated Europeanguideline. Crit Care 2013; 17: R76.
124. Roberts I, Shakur H, Ker K, Coats T, CRASH-2 Trial colla-borators. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2012; 12: CD004896.
125. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlu-sive events, and blood transfusion in trauma patients withsignifican haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
126. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, et al. Anti-fibrinolytic use for minimising per-ioperative allogeneic blood transfusion. Cochrane DatabaseSyst Rev 2011; 1: CD001886.
127. Sentilhes L, Lasocki S, Ducloy-Bouthors AS, Deruelle P, Drey-Fus M, Perrotin F, et al. Tranexamic acid for the preventionand treatment of postpartum haemorrhage. BJA 2014 [2014-00635-JH033. R1 (sous presse)].
128. Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation ofblood loss reduced by tranexamic acid during and after cae-sarean section: a multi-center, randomized trial. Eur J ObstetGynecol Reprod Biol 2004; 112: 154-7.
129. Sekhavat L, Behdad S. Efficacy of tranexamic acid in reducingblood loss after cesarean section. J Matern Fetal NeonatalMed 2009; 22: 72-5.
130. Gungorduk K, Yildirim G, Asicioglu O, Gungorduk OC, Sudol-mus S, Ark C. Efficacy of intravenous tranexamic acid inreducing blood loss after elective cesarean section: a pros-pective, randomized, double-blind, placebo-controlled study. Am J Perinatol 2011; 28: 233-40.
131. Sentürk MB, Cakmak Y, Yildiz G, Yildiz P. Tranexamic acid forcesarean section: a double-blind, placebo-controlled, rando-mized clinical trial. Arch Gynecol Obstet 2013; 287: 641-5.
132. Movafegh A, Eslamian L, Dorabadi A. Effects of intravenoustranexamic acid administration on blood loss during and aftercesarean delivery. Int J Gynaecol Obstet 2011; 115: 224-6.
133. Xu J, Gao W, Ju Y. Tranexamic acid for the prevention ofpostpartum hemorrhage after cesarean section: a double-blind randomization trial. Arch Gynaecol Obstet 2013; 287: 483-8.
134. Goswami U, Sarangi S, Gupta S, Babbar S. Comparative eva-luation of two doses of tranexamic acid used prophylacticallyin anemic parturients for lower segment cesarean section: adouble-blind randomized case control prospective trial. SaudiJ Anaesth 2013; 7: 427-31.
135. Svanberg L, Astedt B, Nilsson IM. Abruptio placentae: treat-ment with the fibrinolytic inhibitor tranexamic acid. ActaObstet Gynecol Scand 1980; 59: 127-30.
136. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huis-soud C, Keita-Meyer H, et al. High-dose tranexamic acidreduces blood loss in postpartum haemorrhage. Crit Care2011; 15: R117.
137. Walzman M, Bonnar J. Effects of tranexaic acid on the coagu-lation and fibrinolytic systems in pregnancy complicated byplacental bleeding. Arch Toxicol Suppl 1982; 5: 214-20.
138. http://ansm.sante.fr/var/ansmsite/storage/original/application/1e76374a64766f1e3ef0ce0239aef36f.pdf
139. Ortmann E, Besser MW, Klein AA. Antifibrinolytic agents in cur-rent anaesthetic practice. Br J Anaesthesia 2013; 111: 549-63.
140. Mackman N. The role of tissue factor and factor VIIa in hemo-stasis. Anesth Analg 2009; 108: 1447-52.
141. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Sha-Piro A, et al. A randomized, double-blind comparison of twodosage levels of recombinant factor VIIa in the treatment ofjoint, muscle and mucocutaneous haemorrhages in personswith haemophilia A and B, with and without inhibitors. rFVIIaStudy Group. Haemophilia 1998; 4: 790-8.
142. Moscado F, Perez F, De La Rubia J, Balerdi B, Lorenzo JI, Senent ML, et al. Successful treatment of severe intra-abdominalbleeding associated with disseminated intravascular coagu-lation using recombinant activated factor VII. Br J Haematol2001; 113: 174-6.
143. Zupancic Salek S, Sokolic V, Viskovic T, Sanjug J, Simic M, Kastelan M. Successful use of recombinant factor VIIa for mas-sive bleeding after caesarean section due to HELLP syndrome. Acta Haematol 2002; 108: 162-3.
144. Sobieszczyk S, Breborowicz GH, Markwitz W, Mallinger S, Adamski D, Kruszýnski Z. [Effect of recombinant activatedfactor VII (RFVIIA; NovoSeven) in a patient in haemor-rhagic shock after obstetrical hysterectomy]. Ginekol Pol2002; 73: 230-3.
145. Bouwmeester FW, Jonkhoff AR, Verheijen RH, van Geijn HP. Successful treatment of life-threatening postpartum hemor-rhage with recombinant activated factor VII. Obstet Gynecol2003; 101: 1174-6.
146. Segal S, Shemesh IY, Blumenthal R, Yoffe B, Laufer N, Ezra Y, et al. Treatment of obstetric hemorrhage with recom-binant activated factor VII (rFVIIa). Arch Gynecol Obstet2003; 268: 266-7.
147. Boehlen F, Morales MA, Fontana P, Ricou B, Irion O, deMerloose P. Prolonges treatment of massive postpartumhemorrhage with recombinant factor VIIa: case report andreview of the literature. Br J Obstet Gynecol 2004; 111: 284-7.
148. Lim Y, Loo CC, Chia V, Fun W. Recombinant factor VIIa afteramniotic fluid embolism and disseminated intravascular coa-gulopathy. Int J Gynaecol Obstet 2004; 87: 178-9.
149. Brice A, Hilbert U, Roger-Christoph S, Fernandez H, Dumenil AS, Descorps-Declère A, et al. [Recombinant activated factorVII as a life-saving therapy for severe postpartum haemor-rhage unresponsive to conservative traditional management]. Ann Fr Anesth Reanim 2004; 23: 1084-8.
150. Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth2005; 94: 592-5.
151. Heilmann L, Wild C, Hojnacki B, Pollow K. Successful treat-ment of life-threatening bleeding after cesarean section withrecombinant activated factor VII. Clin Appl Thromb Hemost2006; 12: 227-9.
152. Hossain N, Shansi T, Haider S, Soomro N, Khan NH, Memon GU, et al. Use of recombinant activated factor VII for mas-sive postpartum hemorrhage. Acta Obstet Gynecol Scand2007; 86: 1200-6.
153. Alfirevic Z, Elbourne D, Pavord S, Bolte A, Van Geijn H, Mercier F, et al. Use of recombinant activated factor VII in pri-mary postpartum hemorrhage: the northern European registry2000-2004. Obstet Gynecol 2007; 110: 1270-8.
154. Ahonen J, Jokela R, Korttila K. An open non-randomized studyof recombinant activated factor VII in major postpartum hae-morrhage. Acta Anaesthesiol Scand 2007; 51: 929-36.
155. Nohira T1, Osakabe Y, Suda S, Takahashi C, Tanaka A, Ikeda K, et al. Successful management by recombinant activatedfactor VII in a case of disseminated intravascular coagulopa-thy caused by obstetric hemorrhage. J Obstet Gynaecol Res2008; 34: 623-30.
156. Bouma LS, Bolte AC, van Geijn HP. Use of recombinant acti-vated factor VII in massive postpartum haemorrhage. Eur JObstet Gynecol Reprod Biol 2008; 137: 172-7.
157. Laird R, Carabine U. Recombinant factor VIIa for major obste-tric haemorrhage in a Jehovah's Witness. Int J Obstet Anesth2008; 17: 193-4.
158. Lewis NR, Brunker P, Lemire SJ, Kaufman RM. Failureof recombinant factor VIIa to correct the coagulopathyin a case of severe postpartum hemorrhage. Transfusion2009; 49: 689-95.
159. Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Janke-Lowitz G, et al. Recombinant activated factor VII in obstetrichemorrhage: experiences from the Australian and New Zea-land Haemostasis Registry. Anesth Analg 2009; 109: 1908-15.
160. Wissa I, Ebeid E, El-Shawarby S, Chandakas S, Kamal T, Hill N. The role of recombinant activated Factor VII in major obs-tetric haemorrhage: the Farnborough experience. J ObstetGynaecol 2009; 29: 21-4.
161. Barillari G, Frigo MG, Casarotto M, Farnia A, Massè B, Wetzl R, et al. The use of fibrinogen concentrate to correct hypo-fibrinogenaemia rapidly during obstetric haemorrhage. Int JObstet Anaesth 2010; 19: 218-34.
162. Arab TS, Al-Wazzan AB, Maslow K. Postpartum hemorrhage ina Jehovah's Witness patient controlled with Tisseel, tranexa-mic acid, and recombinant factor VIIa. J Obstet Gynaecol Can2010; 32: 984-7.
163. Geiger A, Collange O, Samin J, Meyer A, Freys G, Pottecher T. [Efficiency and safety of recombinant activated factor VIIin a case of severe postpartum hemorrhage]. Ann Fr AnesthReanim 2010; 29: 728-31.
164. Huber AW, Raio L, Alberio L, Ghezzi F, Surbek DV. Recom-binant human factor VIIa prevents hysterectomy in severepostpartum hemorrhage: single center study. J Perinat Med2011; 40: 43-9.
165. Jan JY, Lin SY, Lin CH, Lee CN, Fan SZ, Han YY. Recombi-nant activated factor VII as a promising adjuvant therapy forpostpartum hemorrhage in the practice of obstetric anesthe-sia: experience from a university hospital in Taiwan. J ObstetGynaecol Res 2011; 37: 901-7.
166. Kalina M, Tinkoff G, Fulda G. Massive postpartum hemorrhage: recombinant factor VIIa use is safe but not effective. Del MedJ 2011; 83: 109-13.
167. Kayem G, Kurinczuk JJ, Alfirevic Z, Spark P, Brocklehurst P, Knight M. Specific second-line therapies for postpartum hae-morrhage: a national cohort study. BJOG 2011; 118: 856-64.
168. Kobayashi T, Nakabayashi M, Yoshioka A, Maeda M, IkenoueT. Recombinant activated factor VII (rFVIIa/NovoSeven®) inthe management of severe postpartum haemorrhage: initialreport of a multicentre case series in Japan. Int J Hematol2012; 95: 57-63.
169. Afssaps. Protocole thérapeutique temporaire pour le NOVO-SEVEN lors du syndrome hémorragique en obstétrique; 2007. Téléchargeable sur Internet à http://www.santera.fr/doc/omedit/novoseven%20PTT%201.pdf
170. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, SpahnDR. Recommendation on the use of recombinant activatedfactor VII as an adjunctive treatment for massive bleeding: aEuropean perspective. Crit Care 2006; 10: R120.
171. Van Veen EJW, Monteban-Kooistra WE, Meertens JHJM, Lig-tenberg JJM, Tulleken JE, Zijlstra JG. Recombinant humanactivated factor VII in postpartum hemorrhagic shock: thedark side. Intens Care Med 2008; 34: 211-2.
172. Parant O, Guerby P, Bayoumeu F. Spécificités obstétri-cales et anesthésiques de la prise en charge d'unehémorragie du post-partum (HPP) associée à la césa-rienne. J Gynecol Obstet Biol Reprod (Paris) 2014, http://dx.doi.org/10.1016/j.jgyn.2014.10.004.